This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Retinopathy of Prematurity (ROP)
and you are
The phase for this study is not defined.
Show me locations

The purpose

The purpose of this study is to compare the dilating effect of 0, 1, 2 or 3 drops of mydriatic (pupil dilating) in premature infants undergoing routine retinal (eye) screening exams for Retinopathy of Prematurity (ROP).

Provided treatments

  • Drug: 1% phenylephrine and 0.2% cyclopentolate

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01054027. The sponsor of the trial is Georgetown University and it is looking for 15 volunteers for the current phase.
Official trial title:
A Randomized Controlled Trial to Determine the Lowest Effective Dose for Adequate Mydriasis in Premature Infants